Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

  • 0 views
  • 03 Feb, 2021
  • 3 locations
PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

STUDY BACKGROUND AND PURPOSE: Patients with hematological malignancies (blood-related cancers) often develop thrombocytopenia (low platelet count), which can be made worse by cancer treatment. Preventive (prophylactic) platelet transfusion remains the standard of care for thrombocytopenic patients. However, bleeding remains a significant problem in these patients, affecting approximately 20% of patients …

leukemia
myelofibrosis
chronic myelomonocytic leukaemia
stem cell transplantation
myelodysplastic syndromes
  • 29 views
  • 24 Jan, 2021
  • 2 locations
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed. ESCORT-HU Extension study aims at evaluating the long-term safety of Siklos focusing on some questions regarding its safety when used in current practice …

  • 0 views
  • 30 Jan, 2021
  • 77 locations
Sickle Cell Clinical Research and Intervention Program

adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such as hydroxyurea, in preventing organ dysfunction later in life is not clear. Extended follow-up of

hydroxyurea
  • 55 views
  • 11 Mar, 2021
  • 6 locations
Investigation of the Genetics of Hematologic Diseases

effects of hydroxyurea therapy.

hydroxyurea
sickle cell anemia
sickle cell disease
blood disorder
hematologic disorder
  • 94 views
  • 24 Jan, 2021
  • 1 location
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

  • 0 views
  • 28 Jan, 2021
  • 1 location
Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia

MRI monitoring prior to and following clinically indicated transfusions in a subset of patients. Most patients will already be prescribed hydroxyurea as part of their standard of care. Since

hydroxyurea
transfusion dependent thalassemia
anemia
thalassemia
acetazolamide
  • 17 views
  • 24 Jan, 2021
  • 1 location
Predictors and Outcomes in Patients With Sickle Cell Disease

Children with sickle cell disease (SCD) are living longer with the advent of medical advances such as prophylactic penicillin, chronic transfusion, and hydroxyurea. Despite greater longevity in

hydroxyurea
adult care
blood transfusion
  • 8 views
  • 17 Feb, 2021
  • 2 locations
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease

prevent silent and overt strokes in children with SCD, including monthly blood transfusion therapy (for preventing initial and recurrent strokes) and hydroxyurea (for preventing initial strokes). Despite

recurrent strokes
hydroxyurea
stroke
diabetes
infarct
  • 50 views
  • 18 Apr, 2021
  • 6 locations
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT BMT or PBSCT With RIC

This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.

  • 0 views
  • 26 Jan, 2021
  • 1 location